Moderna Inc (NASDAQ:MRNA) has announced positive interim clinical data of its vaccine candidate against Covid-19.
The US biotech firm said the new data reinforces the belief that its mRNA-based vaccine could be effective in preventing infections, without serious side effects.
READ: Avacta says partner Moderna takes collaboration to next level
The third and final phase of trials is pencilled in for July, followed by biologic licence application to the US Food and Drug Administration if successful.
“We are investing to scale up manufacturing so we can maximize the number of doses we can produce to help protect as many people as we can from SARS-CoV-2,” said chief executive Stéphane Bancel.
Shares climbed 30% to US$86.79 at the opening bell on Monday.
